MétaCan
Menu
Back to cohort
Record W2563564231 · doi:10.1016/s1525-0016(16)33621-8

17. Gene Therapy Strategies to Treat Fragile X Syndrome

2015· article· en· W2563564231 on OpenAlexaff
Jason Arsenault, Shervin Gholizadeh, Enea Koxhioni, Sebok K. Halder, David R. Hampson

Bibliographic record

VenueMolecular Therapy · 2015
Typearticle
Languageen
FieldBiochemistry, Genetics and Molecular Biology
TopicGenetics and Neurodevelopmental Disorders
Canadian institutionsUniversity of Toronto
Fundersnot available
KeywordsFMR1Fragile X syndromeTransgeneBiologyGene isoformAdeno-associated virusAutism spectrum disorderVector (molecular biology)Woodchuck hepatitis virusPhenotypeGenetic enhancementGenetically modified mouseGeneViral vectorGeneticsVirologyAutismMedicineFragile xVirusRecombinant DNA

Abstract

fetched live from OpenAlex

Fragile X syndrome (FXS) is a severe debilitating neurodevelopmental disorder of the autism spectrum that results from an aberrant trinucleotide repeat extension in the 5’ region of the FMR1 gene. This extension pathologically reduces or eliminates the expression of the fragile X mental retardation protein (FMRP). FMRP is known to be a scrupulous translational modulator at the synapse and is also known to stabilize and traffic mRNAs important for proper neurological functions. We utilized C57/BL6 mice with a knock-out of the Fmr1 gene (FMRP-KO) in this study because this mouse model reproduces many of the behavioral phenotypes seen in human Fragile X patients. We used adeno-associated viral vectors (AAV) serotype 2/9, which contains the inverted terminal repeats of serotype 2, the human neuron specific synapsin promoter and the largest isoform of FMRP (isoform 1), as well as downstream woodchuck hepatitis virus post-transcriptional regulatory element and a poly A site to elevate mRNA stability, in order to re-introduce FMRP in the brain of neonatal FMRP KO mice. This vector, as well as a cognate null vector containing no transgene used as a control, were administered via bilateral intra-cerebroventricular injections at different early postnatal time points in wild type (WT) and FMRP-KO mice. AAVs were produced and purified by the University of Pennsylvania Vector Core facility. We also investigated whether FMRP overexpression in WT mice could induce behavioral changes. We tested the treated mice in an array of behavioral tests to monitor changes in autism-associated behaviors such as repetitive stereotypical motions, hyperactivity, deficits in social interaction, and general anxiety. Long term FMRP transgene expression was confirmed by immunocytochemistry and quantitative western immunoblotting where strong forebrain and neuron-specific expression was observed. Overall, we observed partial to full amelioration of certain fragile X phenotypes such as motor activity, sensorimotor gating and open field latency in FMRP-KO mice injected with the AAV-FMRP vectors. Also other observations points towards possible pathological effects due to FMRP overexpression in the forebrain of WT mice; an important consideration for future gene therapy of human FXS. These results show that the time of neonatal injection and the total number of AAV particles administered during intra-cerebroventricular injections can affect the efficacy, distribution of transgene expression, and ultimately, the successful reversal of abnormal behaviors.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow)
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Bench or experimental · Consensus signal: Bench or experimental
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.127
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.020
GPT teacher head0.255
Teacher spread0.235 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designBench or experimental
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2015
Admission routes1
Has abstractyes

Explore more

Same venueMolecular TherapySame topicGenetics and Neurodevelopmental DisordersFrench-language works237,207